#### eP073

## **ePoster Viewing**

# Community-acquired pneumonia

COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STAPHYLOCOCCUS AUREUS IN FRANCE: INTERIM RESULTS OF A PROSPECTIVE COHORT STUDY

**M. Saadatian-Elahi**<sup>1</sup>, A. Tristan<sup>1</sup>, Y. Gillet<sup>2</sup>, M. Bes<sup>3</sup>, C. Bouchiat<sup>3</sup>, O. Dumitrescu<sup>3</sup>, C. Picard<sup>4</sup>, L. Argaud<sup>5</sup>, F.

Vandenesch1

<sup>1</sup>Centre National de Référence des Staphylocoques, Hospices Civils de Lyon, Lyon, France ; <sup>2</sup>Les urgences pédiatriques Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Lyon, France ; <sup>3</sup>Centre National de Références des Staphylocoques, Hospices Civils de Lyon, Lyon, France ; <sup>4</sup>Génétique Immunologique, INSERM Université U 980, Paris, France ; <sup>5</sup>Service de réanimation adulte, Hôpital Edouard Herriot, Lyon, France

**Study design:** Prospective cohort study of *S. aureus* community-acquired pneumonia (CAP) with observational and interventional (host genetic) arms including patients with Panton-Valentine Leukocidine (PVL)-associated necrotizing pneumonia (cases), PVL-negative patients (controls), and their family members.

**Objectives:** The main objectives are to: i) investigate the role of PVL as an independent factor of severity in *S. aureus* CAP; ii) identify clinical/biological factors associated with the disease prognostic; iii) assess the level of antibiotic sensitivity of *S. aureus* strains and iv) assess the genetic susceptibility of the host.

## **Methods**

**Setting:** Adult and children presenting with signs and symptoms of *S. aureus* CAP and hospitalized in intensive care units in France. The study started in January 2011.

**Data collection:** Information on demographic variables, medical history, signs and symptoms at presentation, radiological, laboratory and clinical findings during 7 days following hospitalization are collected using an Excel case report form. Biological samples are also collected.

**Statistics:** Study population characteristics were defined by descriptive analysis. Logistic regression analysis was performed to assess factors associated with death.

Genomic: Orfeome of 50 patients and their relatives is assessed by whole genome sequencing.

# Results

**Participants:** To date, 114 patients (?/?:59/55) were enrolled in more than 100 ICUs across France. Clinical and biological data are currently available for 70 patients, including 14 children (<18 years of age) and 56 adults.

**Main results:** Median age was 37.5 and 58 years in PVL-positive (n=38) and PVL-negative (n=32) patients respectively (p=0.001). Prevalence of MRSA strains was 18.8% in PVL-positive and 21.8% in PVL-negative strains. Clinical features of PVL-positive patients differed from the others by higher rates of diarrhoea and erythrodermia at admission and erythrodermia, and pulmonary abscess during hospitalization. Haematological findings were not different between the 2 groups. Appropriate empirical antibiotic therapy and antibiotics with antitoxins properties have been given to the large majority of patients at admission. The overall mortality rate was not different between PVL-negative and PVL-positive patients (40.0% vs 23.3%; p=0.2), but at day-7 the rate of death was significantly higher among PVL-positive patients (31.6% vs 6.6%, p=0.006). Regardless of PVL status, death was associated with haemoptysis (p=0.02) during hospitalization. Peaks of influenza seasons overlapped with an increase in the incidence of *S. aureus* CAP. Orfeome of 30 Patients is currently under analysis.

**Conclusions:** The interim results of our prospective study confirm that PVL remains a factor of severity in *S. aureus* CAP. This necrotizing disease occurs rather in young adults and is characterized by rapid death. The prevalence of MRSA in PVL–positive strains was high and should be taken into consideration to optimize the empirical treatment of severe *S. aureus* CAP. Parallelism between influenza epidemics and higher incidence of CAP suggests a relationship between viral infection and necrotizing pneumonia.